نبذة مختصرة : Background: Invasive fungal disease (IFD) is associated with high morbidity and mortality. Data are lacking regarding physicians' perspectives on the diagnosis and management of IFD in China.
Objectives: To evaluate physicians' perspectives on the diagnosis and management of IFD.
Methods: Based on current guidelines, a questionnaire was designed and administered to 294 physicians working in haematology departments, intensive care units, respiratory departments and infectious diseases departments in 18 hospitals in China.
Results: The total score and subsection scores for invasive candidiasis, invasive aspergillosis (IA), cryptococcosis and invasive mucormycosis (IM) were 72.0 ± 12.2 (maximum = 100), 11.1 ± 2.7 (maximum = 19), 43.0 ± 7.8 (maximum = 57), 8.1 ± 2.0 (maximum = 11) and 9.8 ± 2.3 (maximum = 13), respectively. Although the perspectives of the Chinese physicians were in good overall agreement with guideline recommendations, some knowledge gaps were identified. Specific areas in which the physicians' perspectives and guideline recommendations differed included use of the β-D-glucan test to facilitate the diagnosis of IFD, relative utility of the serum galactomannan test and bronchoalveolar lavage fluid galactomannan test in patients with agranulocytosis, use of imaging in the diagnosis of mucormycosis, risk factors for mucormycosis, indications for initiating antifungal therapy in patients with haematological malignancies, when to start empirical therapy in mechanically ventilated patients, first-line drugs for mucormycosis and treatment courses for IA and IM.
Conclusion: This study highlights the main areas that could be targeted by training programs to improve the knowledge of physicians treating patients with IFD in China.
(© 2023 Wiley-VCH GmbH.)
References: Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71(6):1367-1376.
von Lilienfeld-Toal M, Wagener J, Einsele H, Cornely OA, Kurzai O. Invasive fungal infection. Deutsches Arzteblatt Int. 2019;116(16):271-278.
Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-National prevalence of fungal diseases-estimate precision. J Fungi. 2017;3(4):57.
Valentine JC, Morrissey CO, Tacey MA, et al. A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005-2016. BMC Infect Dis. 2019;19(1):274.
Firacative C. Invasive fungal disease in humans: are we aware of the real impact? Memorias Do Instituto Oswaldo Cruz. 2020;115:e200430.
Long B, Koyfman A. Mucormycosis: what emergency physicians need to know? Am J Emerg Med. 2015;33(12):1823-1825.
Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(suppl_1):S93-S101.
Prakash H, Chakrabarti A. Global epidemiology of Mucormycosis. J Fungi. 2019;5(1):26.
Mühlemann K, Wenger C, Zenhäusern R, Täuber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia. 2005;19(4):545-550.
Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14(7):882-913.
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23-S34.
Valerio M, Munoz P, Rodriguez-Gonzalez C, et al. Training should be the first step toward an antifungal stewardship program. Enferm Infecc Microbiol Clin. 2015;33(4):221-227.
Tan BH, Chakrabarti A, Patel A, et al. Clinicians' challenges in managing patients with invasive fungal diseases in seven Asian countries: an Asia fungal working group (AFWG) survey. Int J Infect Dis. 2020;95:471-480.
Lanternier F, Seidel D, Pagano L, et al. Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: an EFISG, IDWP-EBMT, EORTC-IDG and SEIFEM Survey. Mycoses. 2020;63(5):420-429.
Martin-Loeches I, Antonelli M, Cuenca-Estrella M, et al. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med. 2019;45(6):789-805.
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19(12):e405-e421.
Maertens JA, Girmenia C, Bruggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European conference on infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221-3230.
Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1-e38.
Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433-444.
Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the Management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50.
Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and Management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60.
Theel ES, Doern CD. β-D-glucan testing is important for diagnosis of invasive fungal infections. J Clin Microbiol. 2013;51(11):3478-3483.
He S, Hang J-P, Zhang L, Wang F, Zhang D-C, Gong F-H. A systematic review and meta-analysis of diagnostic accuracy of serum 1,3-β-D-glucan for invasive fungal infection: focus on cutoff levels. J Microbiol Immunol Infect. 2015;48(4):351-361.
Liu L, Li J, Dong H, et al. Diagnostic value of the combinations of bronchoalveolar lavage fluid galactomannan test and serum galactomannan test in invasive pulmonary aspergillosis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019;31(3):331-335.
Valerio M, Vena A, Bouza E, et al. How much European prescribing physicians know about invasive fungal infections management? BMC Infect Dis. 2015;15:80.
Li H, Li M, Yan J, et al. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy. Basic Clin Pharmacol Toxicol. 2020;127(6):495-504.
Cheng L, Xiang R, Liu F, et al. Therapeutic drug monitoring and safety of voriconazole in elderly patients. Int Immunopharmacol. 2020;78:106078.
Diallo K, Thilly N, Luc A, et al. Management of bloodstream infections by infection specialists: an international ESCMID cross-sectional survey. Int J Antimicrob Agents. 2018;51(5):794-798.
Processing Request
No Comments.